PATIENCE: A study to evaluate a standardized approach to treatment of NTM disease (NTM-OB-17 (PATIENCE))

Summary

This study is taking place at multiple care centers across the U.S. It will evaluate the current standard of treatment of nontuberculous mycobacteria (NTM) in people with CF.

This study is for people with cystic fibrosis who were followed in the PREDICT study until they developed NTM disease. Researchers will evaluate how people respond to an NTM treatment algorithm that follows current standard guidelines.

Specimen Information

Status: Specimens are Not yet available, anticipated November, 2024

Blood and urine are collected at the start of treatment for NTM disease, at the end of treatment and at the last follow up (which occurs approximately 1 year after the end of treatment.

<table>
<thead>
<tr>
<th>Visit #</th>
<th>Time From Baseline</th>
<th>Specimens Collected</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>+0 Days</td>
<td>EDTA plasma, Serum, Urine</td>
</tr>
<tr>
<td>2</td>
<td>+12 Months</td>
<td>EDTA plasma, Serum, Urine</td>
</tr>
<tr>
<td>3</td>
<td>+24 Months</td>
<td>EDTA plasma, Serum, Urine</td>
</tr>
</tbody>
</table>

Study Design

Study Type?                Observational
Randomized Study?          No
Placebo Controlled?        No
Length of Participation    5 Years
Number of Study Visits?    20

Additional Information

Phase?                 Not Applicable
Study Sponsor?         Nick, Jerry
Study Drugs?           N/A
Eligibility

Age 6 Years and Older
Mutation(s) No Mutation Requirement
FEV1% Predicated No FEV1 Limit
PA Status N/A
Other Participants have to have been enrolled in the PREDICT study and have been diagnosed with NTM disease.

Study Results

STUDY RESULTS NOT YET AVAILABLE

For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.